GeNeuro SA’s Post

🔵 Currently there is an urgent need for drugs with novel mechanisms of action that can be effective in treating relapsed/refractory multiple myeloma (RRMM) patients and can control long-term disease. In this scenario, B-cell maturation antigen (BCMA)-directed therapies have emerged as promising alternatives ✨.  🗣️ Available in EN & ES (coming soon FR & DE) Gain the latest insights, join our newest free and accredited course 👉https://lnkd.in/g6Y7pV27 #MedicalEducation #BCMA #RRMM

Patients with desmoid tumours experiencing stable disease (SD) can now find hope in the oral gamma secretase inhibitor nirogacestat. Recent study results presented at # ESMOSarcomaAndRareCancers24 reveal significant improvements in pain, cancer-specific symptoms, physical and role functioning, and overall quality of life with nirogacestat treatment. To learn more about this topic, read the #ESMODailyReporter article 👉https://ow.ly/yA8s50QUeg4

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed #MultipleMyeloma not eligible for transplant.  https://lnkd.in/ehNfjUSY

Join Vipul Jairath Principal Investigator at Alimentiv, at the upcoming #DDW2024 for his Research Forum Lecture Presentation. Dr Jairath will be presenting interim results from the VERDICT trial, which aims to determine the optimal treatment target in moderately to severely active #ulcerativecolitis. 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗧𝗶𝘁𝗹𝗲: Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe #ulcerativecolitis: An interim analysis from the VERDICT trial 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗗𝗮𝘁𝗲 & 𝗧𝗶𝗺𝗲: May 20, 2024, from 4:00 to 5:30 PM EDT (UTC –4) 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗧𝗶𝘁𝗹𝗲: IBD Controlled Trials #ddw #ddw24 #Alimentiv

Today we announced positive interim data demonstrating slowing of disease progression in our ongoing Ph. I/II clinical trials of AMT-130 in #huntingtonsdisease. Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 24 months compared to an external control group. In addition, a statistically significant reduction of CSF NfL (a key biomarker of neurodegeneration) was observed in patients treated with AMT-130 compared to baseline. Based on data observed to date, AMT-130 remains generally well-tolerated, with a manageable safety profile at both doses. https://lnkd.in/eDcCyCmE

After listening to the update on this particular AMT-130 disease modifying drug with its true advancements in delaying Huntingtons disease in real time. Using a one time gene therapy has brought a tear to my eye. My non bias opinion below ⬇️ Here is what I’ve learned. Uniqure is doing everything by the books, keeping on the right path of what the FDA requires. Truely not easy 💜 Keeping patients and families safe is a top priority and also NOT skewing their data. They are organized and ready to pump out a phase 3 trial by end of 2024. The end result after two years of comparing high dose patients to low dose patients to natural history patients is quite phenomenal. Fact: if you received the high dose at two years you have not progressed at all. (.2% decline) Low dose patients have had mild but not significant progression. ( .7% decline) Natural history volunteers. Have declined (1.0%). Mind you they compared each specific AMT- 130 patient to a specific declining pateint. Same CAG same age. The data regarding the NFL has all returned to baseline. In both high and low cohorts. The next step is RMAT destination. This, essentially will require patients,families, and friends to start showing up to the meetings with the FDA. Meeting with the FDA is our next step in this truly inspiring medical development. That is delaying HD in its tracks. I would encourage all patients and caregivers. As well as friends and family to jump on these conference calls. Our numbers matter 💜✅💜

Another step in the right direction. Cardiologists know whenever someone has multi-vessel disease, prognosis is somewhat bit dismal as events tend to accumulate faster over time. Glad to see #Repatha is able to power through in risk reduction in the #FOURIER OLE extension study. Link below. A good 4 minutes read time. Title - Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease https://lnkd.in/gwKenuqU #evolocumab #amgen #interventionalcardiology

uniQure shared new data from the first human trial of an AAV-mediated gene therapy in HD! AMT-130 provided therapeutic benefit to participants at 24-months. AMT-130 uses microRNA to target HTT and is delivered in an adeno-associated serotype 5 viral vector (AAV5-miHTT). 🤓    It's wild to know that just over 3 decades ago, scientists discovered the disease-causing CAG repeat expansion in the huntington gene! This mutation drives the production and accumulation of unstable huntingtin protein (HTT) within the brain. While the etiology of the disease is clear, there are no currently approved therapies to modify disease progression. I am hopeful about the future of AMT-130! We are all looking forward to seeing more data. #huntingtonsdisease #viralvector #genetherapy

Don't miss "Team-Based Management of DD-CKD Anemia with New Treatment Strategies" on Wednesday, August 21, from 12:00 - 12:30 PM ET. Register: https://lnkd.in/gmBdmySe This #CME and #CNE symposium on #dialysis-dependent (DD) chronic kidney disease (#CKD) #anemia is designed to encourage the exchange of ideas between leaders in the field and attendees. Led by Kirsten Johansen, MD (United States), the webinar addresses clinical data for hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) for the treatment of DD-CKD anemia, the role of HIF-PHIs in managing DD-CKD anemia, and the importance of a team-based approach to patient treatment and monitoring.

At Virax Biolabs, we are looking to understand the role of the adaptive immune system in symptoms associated with post-viral syndromes such as Long-Covid, whose etiologies are poorly understood. To that end, our ViraxImmune™ platform is aimed at developing a portfolio of T-cell diagnostics focusing on early detection of T-cell exhaustion to enable early treatment interventions. Watch our new #video here to learn more. #vrax #viraxbiolabs #viraximmune #tcells #ivds #longcovid